Fujian Shengdi Pharmaceutical Co., Ltd.
Clinical trials sponsored by Fujian Shengdi Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection could tame high triglycerides Results expected Sep 2026 (estimated)
- New injection aims to shed fluid fast in heart failure patients Results expected Sep 2026 (estimated)
- New pill for weight and diabetes gets first human dosing test Results expected Sep 2026 (estimated)
- New stroke drug HRS-7450 enters Mid-Stage trial Results expected Oct 2026 (estimated)
- New shot could ease sleep apnea without CPAP Results expected Dec 2026 (estimated)
-
Can a new oral drug tame psoriasis? early safety trial begins
Disease control Not yet recruitingThis Phase 1 trial tests a single oral dose of HRS-4139, an experimental drug for psoriasis, in healthy adults aged 18 to 55. Researchers measure how the body absorbs and processes the drug, and watch for any side effects. The goal is to establish a safe dose for future studies i…
Phase 1 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new siRNA injection keep high triglycerides in check for the long haul?
Disease control Not yet recruitingThis Phase 2 trial tests the long-term safety and effectiveness of HRS-7249, an investigational injection that targets a protein called APOC3 to lower triglycerides. The study includes people who previously took part in an earlier HRS-7249 trial, plus new participants aged 18 to …
Phase 2 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Experimental drug aims to tackle both obesity and knee arthritis
Disease control Not yet recruitingThis phase 3 trial tests an injectable drug called ribupatide in people who have both obesity and knee osteoarthritis. The study measures whether ribupatide can reduce knee pain and stiffness, improve joint function, and help with weight loss over 68 weeks. Participants are rando…
Phase 3 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Weekly shot could help shed pounds in obesity trial
Disease control Not yet recruitingThis phase 2 study tests HRS-4729, a once-weekly injection, for weight loss in adults with obesity who do not have diabetes. About 252 participants will receive either the drug or a placebo. The main goal is to see how much body weight changes after 32 weeks compared to a placebo…
Phase 2 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill for weight and diabetes gets first human dosing test
Disease control Not yet recruitingThis early-stage study tests how the body processes HRS9531 tablets under different dosing conditions. It involves 100 healthy adults aged 18-55 with a BMI between 23 and 35. The goal is to measure drug levels and safety, not yet to treat weight or diabetes.
Phase 1 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC